Great talk by Marc Robillard of Tagworks at the Dutch Medicines Days. He talked about their groundbreaking work on antibody-drug conjugates that release their payload through click-to-release chemistry and, thereby, circumvent the need for antibody internalization. www.nature.com/articles/s41...
October 8, 2025 at 7:11 PM
Great talk by Marc Robillard of Tagworks at the Dutch Medicines Days. He talked about their groundbreaking work on antibody-drug conjugates that release their payload through click-to-release chemistry and, thereby, circumvent the need for antibody internalization. www.nature.com/articles/s41...
September 24th, 2026 – 16:00
Christian P.R. Hackenberger, @fmp-berlin.de
P5-labeling for Generating Highly Efficacious ADCs
October 29th, 2026 – 16:00
Marc Robillard, Tagworks Pharmaceuticals
Click-cleavable antibody-drug conjugates
(2/8)
Christian P.R. Hackenberger, @fmp-berlin.de
P5-labeling for Generating Highly Efficacious ADCs
October 29th, 2026 – 16:00
Marc Robillard, Tagworks Pharmaceuticals
Click-cleavable antibody-drug conjugates
(2/8)
June 18, 2026 at 7:37 AM
September 24th, 2026 – 16:00
Christian P.R. Hackenberger, @fmp-berlin.de
P5-labeling for Generating Highly Efficacious ADCs
October 29th, 2026 – 16:00
Marc Robillard, Tagworks Pharmaceuticals
Click-cleavable antibody-drug conjugates
(2/8)
Christian P.R. Hackenberger, @fmp-berlin.de
P5-labeling for Generating Highly Efficacious ADCs
October 29th, 2026 – 16:00
Marc Robillard, Tagworks Pharmaceuticals
Click-cleavable antibody-drug conjugates
(2/8)
Tagworks Pharmaceuticals Initiates Clinical Trials for TGW211, a New HER2-Targeted Radioimmunoconjugate#Netherlands#Nijmegen#HER2-targeted_therapy#Tagworks_Pharmaceuticals#TGW211
Tagworks Pharmaceuticals Initiates Clinical Trials for TGW211, a New HER2-Targeted Radioimmunoconjugate
Tagworks Pharmaceuticals has announced the start of a Phase 0/1 clinical trial for TGW211, a radioimmunoconjugate targeting HER2-positive tumors. This study marks a significant milestone for the company.
third-news.com
October 16, 2025 at 3:52 PM
Tagworks Pharmaceuticals Initiates Clinical Trials for TGW211, a New HER2-Targeted Radioimmunoconjugate#Netherlands#Nijmegen#HER2-targeted_therapy#Tagworks_Pharmaceuticals#TGW211
Tagworks Pharmaceuticals Receives Approval for Innovating HER2+ Tumor Treatment Trial With TGW211#Netherlands#Nijmegen#Tagworks#TGW211#HER2+
Tagworks Pharmaceuticals Receives Approval for Innovating HER2+ Tumor Treatment Trial With TGW211
Tagworks Pharmaceuticals has secured regulatory approval to commence a clinical trial for TGW211, targeting HER2+ tumors using cutting-edge radio-immunotherapy.
third-news.com
October 16, 2025 at 3:44 PM
Tagworks Pharmaceuticals Receives Approval for Innovating HER2+ Tumor Treatment Trial With TGW211#Netherlands#Nijmegen#Tagworks#TGW211#HER2+
Tagworks Pharmaceuticals Announces Clinical Study Approval for TGW211 in Treating HER2+ Tumors#Netherlands#Nijmegen#Tagworks_Pharmaceuticals#HER2+_Cancer#TGW211
Tagworks Pharmaceuticals Announces Clinical Study Approval for TGW211 in Treating HER2+ Tumors
Tagworks Pharmaceuticals has received authorization for its clinical Phase 0/1 study of TGW211, a radiopharmaceutical targeting HER2+ tumors. Initial patient data is anticipated in 2026.
third-news.com
October 16, 2025 at 3:43 PM
Tagworks Pharmaceuticals Announces Clinical Study Approval for TGW211 in Treating HER2+ Tumors#Netherlands#Nijmegen#Tagworks_Pharmaceuticals#HER2+_Cancer#TGW211
Tagworks Pharmaceuticals Unveils Its Innovative Phase 0/1 Clinical Trial for TGW211 Targeting HER2+ Tumors#Netherlands#Nijmegen#Tagworks#TGW211#HER2+
Tagworks Pharmaceuticals Unveils Its Innovative Phase 0/1 Clinical Trial for TGW211 Targeting HER2+ Tumors
Tagworks Pharmaceuticals has received approval for a Phase 0/1 clinical trial for TGW211, a radiopharmaceutical targeting HER2+ tumors, facilitating a new treatment approach.
third-news.com
October 15, 2025 at 11:27 AM
Tagworks Pharmaceuticals Unveils Its Innovative Phase 0/1 Clinical Trial for TGW211 Targeting HER2+ Tumors#Netherlands#Nijmegen#Tagworks#TGW211#HER2+
Tagworks Pharmaceuticals Begins Clinical Trials for Innovative HER2 Tumor Treatment TGW211#Netherlands#Nijmegen#Tagworks#HER2#TGW211
Tagworks Pharmaceuticals Begins Clinical Trials for Innovative HER2 Tumor Treatment TGW211
Tagworks Pharmaceuticals has initiated a Phase 0/1 clinical trial for TGW211, a cutting-edge treatment targeting HER2-positive tumors, designed to revolutionize cancer therapy.
third-news.com
October 15, 2025 at 11:23 AM
Tagworks Pharmaceuticals Begins Clinical Trials for Innovative HER2 Tumor Treatment TGW211#Netherlands#Nijmegen#Tagworks#HER2#TGW211
Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors#Netherlands#ADC_technology#Nijmegen#Tagworks#TGW101
Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors
Tagworks Pharmaceuticals has initiated the third dose of its Phase 1 clinical trial for TGW101, an innovative treatment for advanced solid tumors, showcasing its commitment to pioneering cancer therapies.
third-news.com
September 10, 2025 at 7:47 PM
Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors#Netherlands#ADC_technology#Nijmegen#Tagworks#TGW101
Tagworks Pharmaceuticals Advances Clinical Trial for TGW101 Treatment of Solid Tumors#Netherlands#Nijmegen#TGW101#Tagworks_Pharmaceuticals#Solid_Tumors
Tagworks Pharmaceuticals Advances Clinical Trial for TGW101 Treatment of Solid Tumors
Tagworks Pharmaceuticals has announced the start of the third dose level in its ongoing Phase 1 clinical trial for TGW101, targeting solid tumors. Early results expected in 2026.
third-news.com
September 10, 2025 at 7:06 PM
Tagworks Pharmaceuticals Advances Clinical Trial for TGW101 Treatment of Solid Tumors#Netherlands#Nijmegen#TGW101#Tagworks_Pharmaceuticals#Solid_Tumors
Tagworks Pharmaceuticals Advances TGW101 Study to Third Dose Level for Solid Tumor Treatment#Netherlands#Nijmegen#TGW101#Tagworks_Pharmaceuticals#Solid_Tumors
Tagworks Pharmaceuticals Advances TGW101 Study to Third Dose Level for Solid Tumor Treatment
Tagworks Pharmaceuticals has announced the initiation of the third dosage level in the ongoing Phase 1 study of TGW101, aimed at treating solid tumors. Preliminary data is expected in mid-2026.
third-news.com
September 10, 2025 at 7:05 PM
Tagworks Pharmaceuticals Advances TGW101 Study to Third Dose Level for Solid Tumor Treatment#Netherlands#Nijmegen#TGW101#Tagworks_Pharmaceuticals#Solid_Tumors
Tagworks Pharmaceuticals Advances Clinical Development of TGW101 in Solid Tumor Treatment#oncology#Netherlands#Nijmegen#Tagworks#TGW101
Tagworks Pharmaceuticals Advances Clinical Development of TGW101 in Solid Tumor Treatment
Tagworks Pharmaceuticals has announced the initiation of the third dose level in its Phase 1 trial for TGW101, showing promise for solid tumor treatments.
third-news.com
September 9, 2025 at 11:25 AM
Tagworks Pharmaceuticals Advances Clinical Development of TGW101 in Solid Tumor Treatment#oncology#Netherlands#Nijmegen#Tagworks#TGW101
Tagworks Pharmaceuticals Advances Phase 1 Trial of TGW101 for Solid Tumors Treatment#Cancer_Treatment#Netherlands#Nijmegen#TGW101#Tagworks_Pharmaceuticals
Tagworks Pharmaceuticals Advances Phase 1 Trial of TGW101 for Solid Tumors Treatment
Tagworks Pharmaceuticals recently initiated the third dose level in its Phase 1 trial of TGW101, targeting TAG-72 for solid tumors. Results expected by mid-2026.
third-news.com
September 9, 2025 at 11:17 AM
Tagworks Pharmaceuticals Advances Phase 1 Trial of TGW101 for Solid Tumors Treatment#Cancer_Treatment#Netherlands#Nijmegen#TGW101#Tagworks_Pharmaceuticals
Tagworks Pharmaceuticals Receives FDA Approval for TGW101 Phase 1 Trial and Appoints New CMO#USA#Boston#TGW101#Keith_Orford#Tagworks_Pharmaceuticals
Tagworks Pharmaceuticals Receives FDA Approval for TGW101 Phase 1 Trial and Appoints New CMO
Tagworks Pharmaceuticals has announced FDA approval for TGW101's Phase 1 trial, targeting TAG-72 in advanced tumors, while welcoming Dr. Keith Orford as CMO.
third-news.com
April 22, 2025 at 2:12 PM
Tagworks Pharmaceuticals Receives FDA Approval for TGW101 Phase 1 Trial and Appoints New CMO#USA#Boston#TGW101#Keith_Orford#Tagworks_Pharmaceuticals
Tagworks Pharmaceuticals Secures FDA Approval for TGW101's Clinical Trial and Welcomes New CMO#USA#FDA_Approval#Boston#Tagworks#TGW101
Tagworks Pharmaceuticals Secures FDA Approval for TGW101's Clinical Trial and Welcomes New CMO
Tagworks Pharmaceuticals has received FDA clearance for TGW101's clinical trial, a pioneering ADC targeting TAG-72, and appointed Keith Orford as CMO.
third-news.com
April 22, 2025 at 11:22 AM
Tagworks Pharmaceuticals Secures FDA Approval for TGW101's Clinical Trial and Welcomes New CMO#USA#FDA_Approval#Boston#Tagworks#TGW101
Tagworks Pharmaceuticals Launches Phase 1 Clinical Trial for Innovative Cancer Therapy TGW101#USA#Boston#oncology#TGW101#Tagworks_Pharmaceuticals
Tagworks Pharmaceuticals Launches Phase 1 Clinical Trial for Innovative Cancer Therapy TGW101
Tagworks Pharmaceuticals announces FDA clearance of IND application for TGW101, a novel cancer treatment, and appoints Dr. Keith Orford as CMO.
third-news.com
April 22, 2025 at 11:17 AM
Tagworks Pharmaceuticals Launches Phase 1 Clinical Trial for Innovative Cancer Therapy TGW101#USA#Boston#oncology#TGW101#Tagworks_Pharmaceuticals
Tagworks Pharmaceuticals Receives FDA Approval for TGW101 Clinical Trial Launch#USA#Boston#TGW101#Tagworks_Pharmaceuticals#Keith_Orford
Tagworks Pharmaceuticals Receives FDA Approval for TGW101 Clinical Trial Launch
Tagworks Pharmaceuticals has received FDA approval for TGW101's Phase 1 clinical trial, initiated to evaluate its efficacy as an advanced cancer treatment.
third-news.com
April 22, 2025 at 11:17 AM
Tagworks Pharmaceuticals Receives FDA Approval for TGW101 Clinical Trial Launch#USA#Boston#TGW101#Tagworks_Pharmaceuticals#Keith_Orford
Tagworks Pharmaceuticals Advances Next-Gen Cancer Treatment with FDA Approval for TGW101 Clinical Trial#USA#Boston#Tagworks#TGW101#Keith_Orford
Tagworks Pharmaceuticals Advances Next-Gen Cancer Treatment with FDA Approval for TGW101 Clinical Trial
Tagworks Pharmaceuticals announces FDA clearance for TGW101's Phase 1 trial, targeting solid tumors with groundbreaking precision oncology technology.
third-news.com
April 22, 2025 at 11:14 AM
Tagworks Pharmaceuticals Advances Next-Gen Cancer Treatment with FDA Approval for TGW101 Clinical Trial#USA#Boston#Tagworks#TGW101#Keith_Orford
Found it.
Ta-Ta..
Ta-Ta..
a duck is standing on a counter in a store with a tagworks sign in the background
ALT: a duck is standing on a counter in a store with a tagworks sign in the background
media.tenor.com
July 16, 2025 at 5:47 PM
Found it.
Ta-Ta..
Ta-Ta..
v1.1.1 of tagworks_sdk_flutter Official Flutter SDK for TagWorks, providing deep linking, event tracking, and user engagement features for Android and iOS.
Origin | Interest | Match
Origin | Interest | Match
tagworks_sdk_flutter | Flutter package
Official Flutter SDK for TagWorks, providing deep linking, event tracking, and user engagement features for Android and iOS.
pub.dev
October 23, 2025 at 4:30 AM